NSAID Eye Drops

How topical NSAIDs work and how they differ from steroids

Topical non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis in ocular tissues. Prostaglandins contribute to pain, miosis, blood-aqueous barrier breakdown, and increased vascular permeability — all of which are particularly relevant around ocular surgery.

Unlike topical corticosteroids, NSAIDs do not raise intraocular pressure, do not promote cataract formation, and do not provide broad immunosuppression. Their main clinical value is targeted prostaglandin suppression for analgesia, cystoid macular edema (CME) prophylaxis, and maintaining pupil dilation during surgery. They are commonly paired with topical steroids, which suppress upstream inflammatory mediators through different pathways. Together, the two classes provide more complete perioperative inflammation control and CME risk reduction than either alone.

Common clinical indications

• Cataract surgery — CME prophylaxis and pain: The most common indication. NSAIDs are typically started 1–3 days before surgery and continued for 4–6 weeks postoperatively to reduce CME risk, control pain and photophobia, and help maintain pupil dilation intraoperatively. They complement the topical steroid taper, which is usually shorter.
• CME treatment: When pseudophakic CME (Irvine-Gass syndrome) develops, topical NSAIDs are a first-line treatment, often combined with a topical steroid to address the inflammatory component. Some cases require extended courses.
• Refractive surgery (PRK and LASIK): Short-term pain control early after PRK, especially with a bandage contact lens. Duration is typically brief (2–4 days) to avoid delayed epithelial healing.
• Corneal abrasion or foreign body removal: Very limited duration for significant acute discomfort, with close attention to epithelial healing and follow-up. Not a substitute for treating the underlying cause.
• Allergic conjunctivitis (adjunctive): Ketorolac is FDA-approved for seasonal allergic conjunctivitis, though antihistamine and mast cell stabilizer drops from the allergy page remain first-line.

Comparing agents: brand names, dosing, and clinical profiles

Selection is based on the clinical goal (perioperative CME prophylaxis vs short-term corneal pain), dosing convenience, surface tolerability, and cost. Commonly used ophthalmic NSAIDs:

• Bromfenac 0.07% (Prolensa): Once-daily dosing makes it convenient for perioperative regimens. Generally well tolerated with good penetration to the posterior segment. Commonly chosen for post-cataract CME prophylaxis.
• Nepafenac 0.3% (Ilevro): A prodrug converted intraocularly to amfenac by intraocular hydrolases, designed for posterior segment anti-inflammatory activity. Dosed once daily and commonly used in cataract surgery regimens. The 0.1% formulation (Nevanac) is dosed TID.
• Ketorolac 0.5% (Acular), 0.4% (Acular LS): Widely available with established generic pricing. Effective for short-term pain control and approved for allergic conjunctivitis. Dosed QID typically. Stinging on instillation is the main tolerability issue, which can limit adherence for longer courses.
• Diclofenac 0.1% (Voltaren Ophthalmic): Effective, but some reports associate prolonged use in compromised corneas with a higher risk of epithelial toxicity and corneal melting events. Available generically. Use cautiously and avoid extended dosing on non-healed surfaces.

Higher-risk patients for CME

Some patients warrant more aggressive or prolonged NSAID prophylaxis because of elevated CME risk. These include patients with diabetes (especially with diabetic retinopathy), history of prior CME in the fellow eye, epiretinal membrane, uveitis history, complicated cataract surgery (posterior capsule rupture, vitreous loss), and patients on topical prostaglandin analogs for glaucoma (prostaglandins can contribute to blood-aqueous barrier disruption). In these cases, many clinicians extend the NSAID course beyond the standard 4–6 weeks and monitor with OCT for subclinical macular thickening.

Corneal safety and toxicity concerns

Most patients tolerate topical NSAIDs well, but rare cases of corneal thinning, melting, and perforation have been reported, particularly in eyes with pre-existing surface compromise: neurotrophic keratopathy, severe dry eye, autoimmune connective tissue disease (especially rheumatoid arthritis), prior herpetic keratitis, or large epithelial defects. Risk increases with prolonged dosing on a non-healed corneal surface.

Practical safeguards: Use the shortest effective course on open epithelial defects. Avoid extended NSAID use in high-risk corneas. Discontinue promptly if worsening pain, persistent or enlarging epithelial defect, or signs of progressive thinning occur. Generic formulations may use different preservatives or inactive ingredients that affect tolerability — assess surface response when switching between brands.

Perioperative timing and coordination with steroids

In cataract surgery, NSAIDs are typically started 1–3 days preoperatively to begin suppressing prostaglandin pathways before the surgical stimulus occurs. Postoperatively, the NSAID is continued for 4–6 weeks (longer in high-risk patients), while the topical steroid is tapered on a separate, usually shorter schedule (typically 3–4 weeks). When multiple drops are needed, spacing instillations by at least 5 minutes prevents washout. Clear written instructions about dosing sequence, expected duration, and stop criteria help reduce overuse and minimize epithelial toxicity while preserving CME protection. See the steroids page for taper strategies and formulation selection.